Compare AstraZeneca plc (AZN) vs Uber Technologies Inc (UBER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Uber Technologies Inc — how do they compare? AstraZeneca plc trades at $166.5 (market cap $253.13B), while Uber Technologies Inc trades at $72.41 (market cap $146.73B). The key difference: AstraZeneca plc is the larger of the two by market cap, and AstraZeneca plc pays a 1.92% dividend while Uber Technologies Inc pays none. Which is the better fit depends on your goals.
| AZN | UBER | |
|---|---|---|
Market Cap | $253.13B | $146.73B |
Sector | Health | Industrials |
52-Week High | $209.48 | $100.10 |
52-Week Low | $137.44 | $68.61 |
Enterprise Value | $279.37B | $153.05B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Uber (UBER) trades at $72.08, down 3.3% over the past 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong revenue growth to $52.02B in 2025 and a net income of $10.05B, though Q4 2025 earnings missed expectations. Recent news highlights strategic moves into autonomous vehicles, including robotaxi pilots in Madrid and Munich, alongside cost-cutting measures such as HR layoffs and AI spending caps.
The outlook remains positive with an 81.67% analyst buy rating and a consensus price target of $108.92, suggesting significant upside. Key risks include execution challenges in autonomous driving, competitive pressures in key markets like India, and potential regulatory hurdles. Investors should weigh strong fundamentals against evolving industry dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →
